BioSpace News Archive

Deals

MabVax Therapeutics and Oncotelic Enter into Merger Discussions

Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue

January 4, 2019
·
7 min read
Biotech Bay

Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019

Sangamo Therapeutics, Inc. announced that interim clinical data from the Company’s inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida

January 4, 2019
·
3 min read
Job Trends

Recursion Signs Global Licensing Agreement with the Ohio State Innovation Foundation to Develop REC-2282 to Treat Neurofibromatosis Type 2

Recursion, a clinical-stage biotechnology company combining artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced it has entered into a licensing agreement with the Ohio State Innovation Foundation (OSIF

January 4, 2019
·
4 min read
Drug Development

Tarveda Therapeutics Provides Year-End Update

Data expected from the PEN-221 Phase 2a trial and PEN-866 Phase 1 dose escalation and safety trial in 2019

January 4, 2019
·
4 min read
Biotech Bay

Savonix to Present at Digital Medicine and Medtech Showcase 2019

Showcase Held During J.P. Morgan Healthcare Conference in San Francisco

January 4, 2019
·
1 min read
Drug Development

Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults

Novavax, Inc. (NASDAQ: NVAX) today announced top-line results of its Phase 2 clinical trial of NanoFlu™.

January 4, 2019
·
6 min read
Job Trends

GeneSight® GUIDED Study Published in the Journal of Psychiatric Research

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, todayannounced the publication of the landmark GeneSight GUIDED study in the Journal of Psychiatric Research

January 4, 2019
·
9 min read
Drug Development

Amryt Pharma plc Results of AP101 EASE Phase III trial interim efficacy analysis – IDMC recommends study continues with modest increase in patient numbers

Amryt, a revenue generating orphan drug company focused on acquiring, developing and commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa

January 4, 2019
·
5 min read
Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF alpha Antibody Fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis.

January 4, 2019
·
3 min read
Lamellar to conduct multiple Business Development Meetings about its LAMELLASOME™ technology for safe and effective delivery of nucleic-acid based therapeutics at Biotech Showcase in San Francisco

Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, announces that Dr Alec McLean, CEO; Steven Porteous, Head of Clinical and Regulatory and Dr Lynsey Howard, Head of Pre-clinical Development will be attending Biotech Showcase in San Francisco 7 -9

January 4, 2019
·
4 min read